☆ 4.5 Article

Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial

HEPATOLOGY COMMUNICATIONS (2023)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

Ahmed Omar Kaseb et al.

Summary: This study aimed to evaluate the safety and tolerability of perioperative immunotherapy in patients with resectable hepatocellular carcinoma. The findings suggest that nivolumab alone or in combination with ipilimumab is safe and feasible in this patient population, supporting further studies of immunotherapy in the perioperative setting for hepatocellular carcinoma.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial

Thomas U. Marron et al.

Summary: This study evaluated the clinical activity of neoadjuvant cemiplimab in patients with resectable hepatocellular carcinoma. The results showed that treatment with cemiplimab resulted in significant tumor necrosis and partial response in some patients. Adverse events were common but severe adverse events were rare. These findings contribute to further understanding the clinical benefit of preoperative PD-1 blockade in patients with hepatocellular carcinoma.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma

Yunfan Sun et al.

Summary: This study showed that early-relapse hepatocellular carcinoma (HCC) tumors exhibit innate-like CD8(+) T cells with overexpression of KLRB1 (CD161) and a low cytotoxic state, unlike the exhausted state seen in primary HCC. These cells were associated with a worse prognosis. Additionally, potential immune evasion mechanisms were identified in recurrent tumor cells, which dampen dendritic cell antigen presentation and recruit innate-like CD8(+) T cells.

CELL (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology

BCLC staging system and liver transplantation: From a stage to a therapeutic hierarchy

Quirino Lai et al.

HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL (2021)

Add to Collection

Review Immunology

VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy

Long Yuan et al.

Summary: VISTA, a B7 family member, plays a role in maintaining immune cell quiescence and is a potential target for cancer immunotherapy. It reprograms macrophages and its interaction with ligands is regulated by pH, suggesting targeting intratumoral pH could enhance antitumor immune responses. Additionally, differences among VISTA therapeutics and their potential as candidate immunotherapies are being actively researched.

TRENDS IN IMMUNOLOGY (2021)

Add to Collection

Review Oncology

Vimentin Is at the Heart of Epithelial Mesenchymal Transition (EMT) Mediated Metastasis

Saima Usman et al.

Summary: Vimentin plays a crucial role in cancer growth and metastasis, with the potential to be a therapeutic target to reduce cancer progression and spread. Cells use vimentin to acquire migration abilities and resistance, facilitated by epithelial-mesenchymal transition.

CANCERS (2021)

Add to Collection

Meeting Abstract Oncology

Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial.

Shaohua Li et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study

Zhenggang Ren et al.

Summary: The study aimed to assess the efficacy of sintilimab plus IBI305 versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma in China, showing significant overall survival and progression-free survival benefits with acceptable safety profiles.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Review Gastroenterology & Hepatology

Epidemiology and surveillance for hepatocellular carcinoma: New trends

Amit G. Singal et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

mRECIST for HCC: Performance and novel refinements

Josep M. Llovet et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Review Gastroenterology & Hepatology

2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights

Di-Yang Xie et al.

HEPATOBILIARY SURGERY AND NUTRITION (2020)

Add to Collection

Review Medicine, General & Internal

Hepatocellular Carcinoma

Augusto Villanueva

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Oncology

Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study

Ping Wen et al.

ONCOLOGY RESEARCH (2019)

Add to Collection

Review Gastroenterology & Hepatology

Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west

Jian Lu et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)

Add to Collection

Article Medicine, Research & Experimental

Upregulation of the EMT marker vimentin is associated with poor clinical outcome in acute myeloid leukemia

Sharon Wu et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2018)

Add to Collection

Review Medicine, General & Internal

Hepatocellular carcinoma

Alejandro Forner et al.

LANCET (2018)

Add to Collection

Article Oncology

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2018)

Add to Collection

Editorial Material Oncology

Combination Cancer Immunotherapy in Hepatocellular Carcinoma

Masatoshi Kudo

LIVER CANCER (2018)

Add to Collection

Article Surgery

Transplantation versus hepatectomy for HCC beyond the Milan criteria: A propensity score analysis

Jun-yi Shen et al.

INTERNATIONAL JOURNAL OF SURGERY (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing

Chunhong Zheng et al.

CELL (2017)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results

David P. Cosgrove et al.

RADIOLOGY (2015)

Add to Collection

Article Oncology

Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma

R. Golfieri et al.

BRITISH JOURNAL OF CANCER (2014)

Add to Collection

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

New OPTN/UNOS Policy for Liver Transplant Allocation: Standardization of Liver Imaging, Diagnosis, Classification, and Reporting of Hepatocellular Carcinoma

Christoph Wald et al.

RADIOLOGY (2013)

Add to Collection

Article Gastroenterology & Hepatology

Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma

Myeong Jun Song et al.

JOURNAL OF HEPATOLOGY (2012)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Management of Hepatocellular Carcinoma: An Update

Jordi Bruix et al.

HEPATOLOGY (2011)

Add to Collection

Article Oncology

Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma

Timothy M. Pawlik et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection

Article Cardiac & Cardiovascular Systems

Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study

Johannes Lammer et al.

CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.